Zurich Cantonal Bank
APLS

Zurich Cantonal Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Zurich Cantonal Bank’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,364
Closed -$637K – 2620
2025
Q4 		$637K Buy
+25,364
New +$595K ﹤0.01% 1628

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Zurich Cantonal Bank's APLS Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 27,921 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #1360 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in APLS as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in APLS in Q3 2018 and has held it in 30 quarters since. The position peaked at $1.2M in Q4 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Zurich Cantonal Bank held 27,921 shares of Apellis Pharmaceuticals worth $1.12M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • Apellis Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1360 holding.
  • Zurich Cantonal Bank first reported a position in Apellis Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
  • Zurich Cantonal Bank's Apellis Pharmaceuticals position peaked at $1.2M in Q4 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.